Skip to main content

Table 1 Summary of Metastatic/Primary Stages and CMS Classes in 2250 Moffitt Colorectal Cancers

From: An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

CMS Classes1

N (%)

Age Median2

Sex3 N (%)

Metastatic4 N (%)

Primary4N (%)

Primary Stages5 N (%)

I

II

III

IV

NA

CMS1

305 (13.6)

68.7 yr (16.7 -87.0 yr)

F 182 (8.1) M 123 (5.5)

65 (2.9)

240 (10.7)

38 (2.6)

108 (7.3)

69 (4.6)

18 (1.2)

7 (0.5)

CMS2

675 (30.0)

63.0 yr (19.8 -87.5 yr)

F 283 (12.6) M 391 (17.4)

276 (12.2)

399 (17.7)

84 (5.7)

130 (8.8)

138 (9.3)

32 (2.2)

15 (1.0)

CMS3

347 (15.4)

66.6 yr (24.3 -87.1 yr)

F 176 (7.8) M 171 (7.6)

39 (1.7)

308 (13.7)

82 (5.5)

78 (5.3)

105 (7.1)

29 (2.0)

14 (0.9)

CMS4

685 (30.4)

62.0 yr (20.3 -87.6 yr)

F 316 (14.1) M 369 (16.4)

277 (12.3)

408 (18.1)

38 (2.6)

132 (8.9)

167 (11.2)

52 (3.5)

19 (1.3)

CMS-NA

238 (10.6)

64.4 yr (30.4 -85.9 yr)

F 109 (4.8) M 129 (5.7)

107 (4.8)

130 (5.8)

24 (1.6)

33 (2.3)

57 (3.8)

12 (0.8)

4 (0.3)

Total

2250 (100.0)

64.3 yr (16.7 -87.6 yr)

F 1066 (47.4) M 1183 (52.6)

764 (34.0)

1485 (66.0)

266 (17.9)

481 (32.4)

536 (36.1)

143 (9.7)

59 (4.0)

  1. Note: 1CMS-NA tumors are those not applicable to any single CMS1-4 subtype;
  2. 22147 patients had approximate age information;
  3. 3The percentages were calculated based on 2249 patients who had approximate sex information; F – female patients; M – male patients;
  4. 4The percentages were calculated based on 2249 patients who had approximate metastatic/primary tumor information;
  5. 5The percentages were calculated based on 1485 primary tumor patients among whom 1426 patients had approximate primary Stage I-IV information whereas 59 patients did not (NA)